References

  1. Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: a Blueprint for Transforming Prevention, Care, Education and Research. Washington, DC: The National Academies Press; 2011. http://books.nap.edu/openbook.php?record_id=13172&page=1. Accessed November 16, 2014.
  2. The American Academy of Pain Medicine. Use of Opioids for the Treatment of Chronic Pain, a statement from the American Academy of Pain Medicine. The American Academy of Pain Medicine. http://www.painmed.org/files/use-of-opioids-for-the-treatment-of-chronic-pain.pdf. Published 2013. Accessed November 16, 2014.
  3. The White House. Epidemic: Responding to America’s Prescription Drug Abuse Crisis. The White House. http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan.pdf. Published 2011. Accessed November 16, 2014.
  4. The National Alliance for Model State Drug Laws and The National Safety Council. Prescription Drug Abuse, Addiction and Diversion: Overview of State Legislative and Policy Initiatives, Part 3: Prescribing of Controlled Substances for Non-Cancer Pain. http://www.namsdl.org/library/7176E80B-1C23-D4F9-745A3D08D1C82161/. Published October 2013. Accessed December 14, 2014.
  5. U.S. Food and Drug Administration. Guidance for Industry Abuse-Deterrent Opioids—Evaluation and Labeling. U.S. Food and Drug Administration. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf.
  6. NIH Medline Plus. Chronic pain: symptoms, diagnosis, & treatment. NIH Medline Plus. 2011;6(1):5,6,9. http://www.nlm.nih.gov/medlineplus/magazine/issues/spring11/articles/spring11pg5-6.html.
  7. Chou R, Huffman LH. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147(7):492-514.
  8. Task Force on Taxonomy of the International Association for the Study of Pain. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms: Second Edition. International Association for the Study of Pain. http://www.iasp-pain.org/files/Content/ContentFolders/Publications2/FreeBooks/Classification-of-Chronic-Pain.pdf. Published 1986. Updated 1994. Accessed December 14, 2014.
  9. Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician. 2008;11(2 Suppl):S155-S180. http://www.painphysicianjournal.com/linkout_vw.php?issn=1533-3159&vol=11&page=S155. Accessed November 16, 2014
  10. Centers for Disease Control and Prevention. Policy Impact: Prescription Painkiller Overdoses. Centers for Disease Control and Prevention. http://www.cdc.gov/HomeandRecreationalSafety/pdf/PolicyImpact-PrescriptionPainkillerOD.pdf. Published November 2011. Accessed November 16, 2014.
  11. Willy, Mary. Risk Evaluation and Mitigation Strategy for Opioid Analgesics: Final Report of the Metrics Working Group. U.S. Food and Drug Administration. June 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/ucm217510.pdf. Accessed December 15, 2014.
  12. Jedinger, N., Khinast, J., Roblegg, E. The design of controlled-release formulations resistant to alcohol-induced dose dumping—a review [abstract]. Eur J Pharm Biopharm. 2014;87(2):217-226. http://www.ncbi.nlm.nih.gov/pubmed/24613542. Accessed November 16, 2014.
  13. U.S. Food and Drug Administration. FDA Statement: FDA Commissioner Margaret A. Hamburg Statement on Prescription Opioid Abuse. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391590.htm. Published April 3, 2014. Accessed November 16, 2014.
  14. Arnstein P, St. Marie B. Managing Chronic Pain With Opioids: A Call for Change. Nurse Practitioner Health Foundation. http://www.nphealthcarefoundation.org/programs/downloads/white_paper_opioids.pdf. Published December 15, 2010. Accessed November 16, 2014.
  15. American Academy of Family Physicians. Safe Use, Storage, and Disposal of Opioid Drugs. Available at: http://familydoctor.org/familydoctor/en/drugs-procedures-devices/prescription-medicines/safeuse.html. Published July 2013. Accessed November 25, 2014.
  16. U.S. Food and Drug Administration. A Brief Overview of Risk Evaluation & Mitigation Strategies (REMS). U.S. Food and Drug Administration. http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM328784.pdf. Accessed November 12, 2014.
  17. Centers for Medicare & Medicaid Services. The Role of A Prescription Drug Monitoring Program in reducing Prescription Drug Diversion, Misuse, and Abuse. Available at: http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Downloads/prescriptiondrug-monitoring-factsheet.pdf. Accessed November 24, 2014.
  18. U.S. Department of Health and Human Services. Prescription Drug Monitoring Program Interoperability Standards: A Report to Congress. U.S. Department of Health and Human Services. http://www.healthit.gov/sites/default/files/fdasia1141report_final.pdf. Published September 2013. Accessed December 14, 2014.
  19. U.S. Drug Enforcement Administration. Drug Scheduling. Drug Schedules. U.S. Drug Enforcement Administration. http://www.dea.gov/druginfo/ds.shtml. Accessed November 14, 2014.
  20. U.S. Department of Justice and U.S. Drug Enforcement Administration. Office of Diversion Control. Program Description. U.S. Department of Justice and U.S. Drug Enforcement Administration. http://www.deadiversion.usdoj.gov/prog_dscrpt/index.html. Accessed November 12, 2014.
  21. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: volume 1: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2011. http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.pdf Published September 2011. Accessed November 14, 2014.
  22. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-2620. doi:10.1001/jama.2008.802. http://jama.jamanetwork.com/article.aspx?articleid=183046. Accessed November 16, 2014.
  23. National Institute on Drug Abuse. DrugFacts: Prescription and Over-the-Counter Medications. NIH: National Institute on Drug Abuse. http://www.drugabuse.gov/publications/drugfacts/prescription-over-counter-medications. Revised November 2014. Accessed November 16, 2014.
  24. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Center for Drug Evaluation and Research (CDER). Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. U.S. Food and Drug Administration. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.pdf. Published December 2002. Accessed November 16, 2014.
  25. National Institute on Drug Abuse. (2011). Topics in Brief: Prescription Drug Abuse. Accessed December 5, 2014.
  26. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444-59.
  27. Data on file: Versta Research. Survey on Pain Matters, Report of Findings from the Chronic Pain and Abuse Deterrence Technology Surveys of Patients and Healthcare Professionals. 2015.
  28. K. Dijkstra, M.E. Pietrse, A. Th. H. Pruyn. Individual differences in reactions towards color in simulated healthcare environments: The role of stimulus screening ability. Journal of Environmental Psychology. 28(3):268–277. Published September 2008.
  29. Morton Walker. The Power of Color. New York, Avery Publishing Group. 1991; 50-52.
  30. Jo Silvester and Dr Efrosyni Konstantinou. Lighting, Well-being and Performance at Work. City University London & The Centre for Performance at Work. Environment and Behavior. 2010; 4-19. http://www.cassknowledge.com/sites/default/files/article-attachments/lighting-work-performance-cass.pdf.
  31. Sibel S. Dazkir, Marilyn A. Read. Furniture Forms and Their Influence on Our Emotional Responses Toward Interior Environments. Oregon State University. 2011; 1. http://eab.sagepub.com/content/44/5/722.
  32. Janet Beal. How to Install Floor Tiles to Make a Room Look Larger. SF Gate Home Guides. 2013. http://homeguides.sfgate.com/install-floor-tiles-make-room-look-larger-34928.html.
  33. Dr. Zackary Berger, Talking to Your Doctor: A Patient's Guide to Communication in the Exam Room and Beyond. Rowman & Littlefield Publishers; 1 edition. 2013
  34. Rabinowitz, I, Tamir, R, Reis, A. Length of patient's monologue, rate of completion, and relation to other components of the clinical encounter. British Medical Journal. 2004;501-502.
  35. Beckman HB, Frankel RM. The effect of physician behavior on the collection of data. Annals of Internal Medicine, 1984;692-696.
  36. Centers for Disease Control and Prevention. Injection Safety: Risks of Healthcare-associated Infections from Drug Diversion. Centers for Disease Control and Prevention. http://www.cdc.gov/injectionsafety/drugdiversion/. Published June 2014. Accessed November 19, 2015